What biomarker tests are recommended for Ovarian Cancer

Biomarker Testing for Ovarian Cancer

I'll walk you through what biomarker tests are recommended for ovarian cancer and how they're used in clinical care.

Primary Biomarker: CA-125

CA-125 is the most important and widely used biomarker for ovarian cancer. According to the NCCN Guidelines, CA-125 testing is recommended as part of your preoperative workup (before surgery) because:

• Serum CA-125 levels correlate with the extent of disease (how far the cancer has spread)
• It has prognostic value, meaning it helps doctors understand your prognosis and plan treatment
• It's useful for monitoring your response to therapy during and after treatment
• It can help detect recurrence (cancer returning) during follow-up surveillance

Important context: CA-125 levels tend to follow your disease course, especially if your levels were elevated before treatment started.

Secondary Biomarker: HE4

HE4 (Human Epididymis Protein 4) is another marker that's sometimes tested. According to NCCN Guidelines:

• Some evidence suggests HE4 may be a useful prognostic marker
• It decreases during treatment response
• It may help detect recurrence earlier than CA-125 alone
• NCCN panel members sometimes test HE4 in patients who don't have elevated CA-125, since it can be useful for future monitoring

However, the NCCN Guidelines currently do not recommend routine HE4 as part of standard preoperative workup because results vary across studies.

Other Tumor Markers (Less Common Ovarian Cancers)

Depending on your specific cancer type, your doctor may test additional markers:

• Inhibin - for granulosa cell tumors (a type of sex cord-stromal tumor)
• AFP (Alpha-fetoprotein) - for germ cell tumors
• Beta-hCG (Human chorionic gonadotropin) - for germ cell tumors
• LDH (Lactate dehydrogenase) - for germ cell tumors
• CEA (Carcinoembryonic antigen) - may be used in certain cases
• CA19-9 - particularly for mucinous ovarian tumors

These markers are especially helpful if you have a less common ovarian cancer type, as they can:

• Help with intraoperative diagnosis (during surgery)
• Facilitate post-treatment monitoring for recurrence
• Provide prognostic information

Important Clarification: What These Tests Are NOT For

According to NCCN Guidelines, it's critical to understand that:

• Biomarker tests are NOT screening tools for detecting ovarian cancer in women without symptoms
• Multi-biomarker assays (like OVA1) are not recommended for screening or as stand-alone diagnostic tests
• These tests are for preoperative assessment only - meaning they help evaluate a mass that's already been found on imaging

The Society of Gynecologic Oncology (SGO) and the FDA have specifically stated that tests like OVA1 should not be used as screening tools in asymptomatic women.

Molecular Testing (BRCA and Homologous Recombination Status)

Beyond traditional biomarkers, NCCN Guidelines strongly recommend that upon pathologic confirmation of ovarian cancer, you should have:

• Germline BRCA1/2 testing - to determine if you carry a hereditary mutation
• Somatic (tumor) BRCA1/2 testing - testing the cancer cells themselves
• Homologous recombination (HR) status - assessing whether your cancer is HR-deficient (HRD) or HR-proficient (HRP)

Why this matters: This molecular information directly informs whether you're eligible for PARP inhibitor maintenance therapy, which can significantly improve outcomes for patients with stage II-IV disease who respond to initial chemotherapy.

Questions to Ask Your Oncologist

Based on this information, here are specific questions to discuss with your care team:

1. "Which biomarkers will you be testing at baseline, and why?"
2. "Will you be testing my CA-125 level, and how will you use it to monitor my treatment response?"
3. "Do you recommend HE4 testing for my specific situation?"
4. "Have you ordered BRCA and homologous recombination testing? When will those results be available?"
5. "How will these biomarker results influence my treatment plan?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines Version 3.2025 for Ovarian Cancer